Ipsen CEO steers clear of gene therapy despite rare disease push
Ipsen NHS Study Published - IFOPA - International Fibrodysplasia Ossificans Progressiva Association
Ipsen Goes All In on Neuro with $1 Billion+ Deal For Exicure's Oligonucleotides | BioSpace
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation - Global
IPSEN: Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy | FDA Reporter
Ipsen and Medetia join forces to accelerate early research in rare disease - Global
Ipsen puts patients first
Emirates Oncology Society And Ipsen Break Guinness World Record For Largest Awareness Ribbon | Press Release Network
Press Releases - Ipsen UK
LeaveRussia: Ipsen is Pausing New Investments in Russia
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 | Business Wire
Ipsen ships 18 furnaces in Q2, including 210,000-pound capacity vacuum furnace | ASM International
FOP Fnd NL on X: "Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies ...for children under the age of 14 because of some cases with early growth plate closure...
Ipsen media library
Press releases
Press Releases - Ipsen UK
06-01-2016-PR-Ipsen-Galderma-APAC-Dysport-Aesthetics
Ipsen is officially recognized as a great place to work worldwide - Global
Ipsen to acquire exclusive rights to investigational ERK inhibitor as part of its existing research collaboration with AGV Discovery | Liberi Group
Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief | Business Wire
Ipsen: a dynamic, fast-growing specialty care powerhouse
Ipsen Inc. | Aviation Pros
